To study characteristics, treatment approaches and outcome of HIV-infected patients with malignant lymphoma in the combination antiretroviral therapy (cART) era. HIV-infected persons diagnosed with non-Hodgkin lymphoma or Hodgkin lymphoma will be included. The choice of treatment is not specified by the registry study. However, the type of antineoplastic treatment should follow national or international recommendations and guidelines. Data will be pseudonymized by the data manager of the treating institution. Central data management is located at Red Cross Hospital Munich, Germany.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histology or cytology proven non-Hodgkin lymphoma or Hodgkin lymphoma
HIV-infection at time of lymphoma diagnosis
Lymphoma diagnosis since 01.01.2010
Adult patients ≥ 18 years
Written informed consent
You may not be if
HIV-diagnosis \> 3 months after the diagnosis of malignant lymphoma
Non-Compliance or lack of opportunity for follow-up (for the prospective part of the study)